Mastocytoma: How Mast Cell Tumors Are Diagnosed and Treated

A mastocytoma is a tumor made up of mast cells, a type of immune cell found throughout the body’s connective tissues. The term shows up most often in veterinary medicine, where mast cell tumors are one of the most common skin cancers in dogs, but it also applies to a specific form of human cutaneous mastocytosis that typically appears in infancy. Despite the shared name, the behavior of these tumors varies enormously depending on the species affected, the location in the body, and the genetic mutations driving the growth. A dog’s skin lump and a baby’s reddish-brown patch both qualify as mastocytomas, yet the prognosis and treatment look nothing alike.

What Mast Cells Actually Do

Mast cells are immune sentinels stationed in skin, the lining of the gut, airways, and around blood vessels. They are best known for triggering allergic reactions by releasing histamine and other chemical mediators, but their job description is far broader. They participate in wound healing, tissue remodeling, and both innate and adaptive immunity, including immune tolerance.¹ When mast cells accumulate at the edge of a tumor, they can promote blood vessel formation, remodel surrounding tissue to help the tumor spread, and dampen the immune system’s ability to reject the growing mass.² That dual nature, useful in healthy tissue but dangerous when dysregulated, is central to understanding why mast cell tumors can range from harmless bumps to life-threatening cancers.

The KIT Mutation at the Center of the Problem

Most mast cell tumors share a common molecular thread: mutations in the KIT gene. KIT codes for a receptor on the mast cell surface that, when activated normally, tells the cell to grow, divide, and survive. Gain-of-function mutations essentially jam that receptor in the “on” position, so the cell keeps proliferating without the usual signals telling it to stop.³ These mutations turn up frequently in abnormal mast cells across species, appearing in dogs, cats, and humans.⁴ The specific location of the mutation within the gene matters: some mutations respond well to targeted drugs, while others are stubbornly resistant. That shared genetic driver has made mast cell tumors a valuable model for comparative oncology, where findings in one species feed directly into research for another.⁵

Canine Mast Cell Tumors, the Most Common Scenario

When veterinarians say “mastocytoma,” they usually mean a canine cutaneous mast cell tumor. These are among the most frequently diagnosed skin cancers in dogs. They show up as lumps in or under the skin, and their appearance is notoriously unreliable: they can mimic lipomas, insect bites, warts, or almost any other skin mass. About 70% occur in the skin itself, with another roughly 20% classified as subcutaneous (sitting in the fat layer just beneath the skin).⁶ A mast cell tumor can swell and shrink unpredictably because the cells release histamine when disturbed, causing redness, swelling, and itching in the area around the mass.

Certain breeds face a dramatically higher risk. Boxers, Labrador Retrievers, Golden Retrievers, French Bulldogs, Pugs, American Staffordshire Terriers, and Shar-Peis are all overrepresented. The risk is not uniform across those breeds, though. Boxers and Pugs tend to develop low-grade tumors with a favorable prognosis, while Shar-Peis carry the highest risk of developing high-grade, aggressive tumors.⁷ Age at diagnosis varies by breed as well: Labrador Retrievers tend to be diagnosed between 4 and 6 years of age, whereas Boxers and French Bulldogs peak between 7 and 10 years.⁸ Gender does not appear to play a meaningful role in overall risk, though one study noted a male predominance in French Bulldogs and a female predominance in Shar-Peis.⁹

Location on the body matters, too. Tumors on the limbs are the most common overall, but certain high-risk anatomic sites, particularly the scrotum, inguinal area, and axilla, carry a much higher likelihood of being high-grade.¹⁰

How Canine Mast Cell Tumors Are Diagnosed and Graded

The first step is usually a fine-needle aspirate, where a veterinarian inserts a small needle into the lump and examines the collected cells under a microscope. Mast cells are identified by their distinctive purple-staining granules when treated with certain dyes.¹¹ This gives a rapid presumptive diagnosis, but full grading requires a biopsy specimen examined by a pathologist.

Two grading systems are widely used. The older Patnaik system assigns tumors to grades I, II, or III. The newer Kiupel system simplifies this into just two categories, low-grade and high-grade. Research comparing the two has shown that the two-tier Kiupel system is more consistent between pathologists and better at predicting outcome. Grade III under the Patnaik system consistently maps to high-grade in the Kiupel system, and grade I consistently maps to low-grade. The trouble has always been grade II, which is where most tumors land. About 86% of Patnaik grade II tumors turn out to be low-grade by Kiupel criteria, while the remaining 14% are high-grade, and those two subsets have vastly different survival: roughly 94% one-year survival for the low-grade group versus 46% for the high-grade group.¹² The Kiupel system also shows higher agreement between different pathologists reading the same slides, making it a more reproducible prognostic tool.¹³

Beyond grading, several biomarkers help predict how a tumor will behave. The mitotic index (how many cells are actively dividing), Ki67 expression (another measure of cell division), and the pattern of KIT protein staining within the tumor cells all carry prognostic weight. Abnormal KIT localization patterns and high Ki67 values are associated with shorter survival and a greater likelihood of recurrence or spread.¹⁴ ¹⁵

Staging and the Role of Lymph Nodes

Once a mast cell tumor is confirmed, staging determines whether it has spread. Regional lymph nodes are the first place veterinary oncologists look. Newer imaging techniques have made this more precise. Lymphoscintigraphy (a nuclear medicine scan) can detect the sentinel lymph node in over 90% of cases, and CT-based lymphography and contrast-enhanced ultrasound achieve similar detection rates.¹⁶ The sentinel node concept, borrowed from human oncology, identifies the first lymph node to which a tumor is likely to drain. Knowing which node to biopsy avoids removing nodes that have nothing to do with that tumor’s drainage path. Even for low-grade tumors, lymph node sampling has become increasingly standard, because spread to a node can change the treatment plan entirely.

Treating Canine Mast Cell Tumors

Surgery is the backbone of treatment for most canine mast cell tumors. The critical question is margins, meaning how much apparently healthy tissue the surgeon removes around the visible tumor. A systematic review of the evidence found that lateral margins of 2 centimeters and one fascial plane deep are associated with incomplete excision rates below about 10% and recurrence rates near zero for low- and intermediate-grade tumors smaller than 4 centimeters.¹⁷ When margins come back narrow or incomplete on pathology, a scar revision procedure is one option. In one study of 54 scar revisions, local recurrence occurred in under 4% of cases, and residual tumor was uncommon.¹⁸

When surgery alone is not enough, radiation therapy fills the gap. A multicenter study of 300 dogs that received radiation after incomplete or narrow surgical excision reported a recurrence rate of about 7%, substantially lower than the up to 36% recurrence seen with surgery alone for incompletely removed tumors.¹⁹ For high-grade tumors specifically, treating regional lymph nodes with radiation, even when they appear clean on biopsy, significantly extends the time before the cancer returns. One study found that prophylactic lymph node irradiation pushed progression-free survival from under 200 days to well over 2,000 days in dogs with high-grade tumors.²⁰

Tyrosine Kinase Inhibitors

Because KIT mutations drive many mast cell tumors, drugs that block the KIT receptor’s activity (tyrosine kinase inhibitors, or TKIs) have become an important treatment option. Toceranib and masitinib are the TKIs approved for veterinary use. A meta-analysis comparing TKIs to the traditional chemotherapy drug vinblastine found that TKIs produced higher initial response rates. However, dogs treated with vinblastine had longer overall survival and progression-free survival. The picture flipped for dogs whose tumors carried a confirmed KIT mutation: in those cases, TKI-treated dogs survived longer than vinblastine-treated dogs.²¹ That finding underscores why mutation testing matters: a drug that works beautifully against a mutated receptor may offer less benefit when the tumor is driven by something other than KIT.

Tigilanol Tiglate, a Newer Intratumoral Option

A more recent addition to the veterinary toolkit is tigilanol tiglate, a small molecule injected directly into the tumor. Rather than targeting a single receptor, it triggers rapid destruction of the tumor through hemorrhagic necrosis, followed by sloughing of the dead tissue and healing by secondary intention.²² In a randomized controlled trial, 75% of treated dogs achieved a complete response by 28 days, compared with 5% of control dogs. Within hours to days of injection, the treated site develops bruising and swelling; the tumor then sloughs off over roughly 3 to 10 days, leaving a wound that heals on its own.²³ This approach suits tumors in locations where wide surgical margins are difficult, though it is not intended for high-grade or metastatic disease.

Supportive Medications

Because mast cell tumors release histamine and other inflammatory mediators, dogs undergoing treatment often receive antihistamines targeting both H1 and H2 receptors. These control the itching, redness, and gastrointestinal upset that can accompany any disturbance of the tumor, including surgery or even a routine needle aspirate.²⁴ Gastroprotectants are also commonly prescribed, since histamine stimulates stomach acid secretion and mast cell tumors can cause ulcers.

Feline Mast Cell Tumors

In cats, the picture is different enough that it deserves separate attention. Mast cell tumors are the most common splenic tumor in cats, the second most common skin tumor, and the third most common intestinal tumor.²⁵ The cutaneous form in cats is generally less aggressive than in dogs, and many skin-based feline mast cell tumors are cured with surgery alone. The visceral forms, especially splenic and intestinal, carry a more guarded prognosis. Siamese cats appear to be predisposed to cutaneous mast cell tumors, and these cats sometimes develop multiple skin lesions that may spontaneously regress. The divergence in behavior depending on tumor location means that a diagnosis of “mast cell tumor” in a cat requires different conversations depending on whether the lump is on the skin, in the spleen, or in the gut.

Human Mastocytoma and Mastocytosis

In people, the term “mastocytoma” usually refers to a solitary cutaneous mastocytoma, a form of cutaneous mastocytosis that shows up as a single yellowish-brown to reddish-brown nodule or plaque. It typically appears in the first few months of life. Rubbing or scratching the lesion produces localized hiving and redness, a characteristic response called Darier’s sign.²⁶ In most children, these lesions gradually fade on their own by puberty and do not develop into systemic disease. Treatment focuses on managing symptoms: antihistamines (both H1 and H2 types) are first-line, with short courses of topical corticosteroids for flare-ups. Phototherapy is an option when antihistamines are not enough.²⁷

Systemic mastocytosis, where abnormal mast cells accumulate in internal organs, especially the bone marrow, is a different beast. It is rare and ranges from indolent forms, which can be managed symptomatically for years, to aggressive variants that behave like a blood cancer. The molecular driver in the majority of adult systemic mastocytosis cases is a specific KIT mutation called D816V. Older drugs like imatinib, which works against many KIT mutations, do not touch this particular one. That gap drove development of newer targeted therapies. Midostaurin was the first agent approved for advanced systemic mastocytosis, followed by avapritinib, which is more selective for the D816V mutation.²⁸ Real-world data comparing the two suggests avapritinib leads to longer survival: in one retrospective analysis, patients on avapritinib had significantly longer overall survival than those on midostaurin, and achieved a greater reduction in serum tryptase, a marker of mast cell burden.²⁹

Why Canine Tumors Matter for Human Medicine

Dogs and humans share the same mutated gene driving their mast cell diseases, which makes canine mast cell tumors a uniquely useful natural model for studying KIT-driven cancers in people. Canine cutaneous mast cell tumors harbor KIT abnormalities that closely resemble those found in human gastrointestinal stromal tumors (GISTs), another KIT-dependent cancer.³⁰ Because dogs develop these tumors spontaneously, live with their owners rather than in a lab, and progress through the disease on a compressed timeline, clinical trials in dogs can generate data on new KIT-targeting drugs faster than human trials can. Results then feed back into human drug development. Several drugs now used in human oncology were tested in canine patients first, and efforts continue to develop new strategies that benefit both species.³¹ Clinical responses to TKIs remain unpredictable and often temporary in both dogs and people, so the next generation of research is exploring combination therapies and alternative targets beyond KIT alone.

When to Worry About a Lump

For dog owners, the practical takeaway is that any new lump or bump that appears on your dog’s skin should be aspirated rather than watched. Mast cell tumors cannot be reliably identified by look or feel, and early detection makes a substantial difference in outcome. A fine-needle aspirate is quick, inexpensive, and usually does not require sedation. If the aspirate confirms mast cells, the conversation shifts to staging, grading, and a treatment plan that may be as simple as a single surgery or as complex as a multi-modal protocol involving radiation and targeted drugs.

For parents of infants who develop a solitary reddish-brown skin nodule that hives up when rubbed, a pediatric dermatologist can usually confirm a mastocytoma clinically using Darier’s sign without an invasive biopsy. The overwhelming majority of these childhood lesions resolve without aggressive treatment. The rare transition to systemic disease is something a specialist can monitor with periodic checks, but the odds strongly favor a benign course.

Across species, the unifying lesson of mast cell tumors is that the same gene mutation can produce wildly different outcomes depending on where the tumor sits, what secondary mutations are present, and how the host immune system interacts with the growing mass. That complexity frustrates one-size-fits-all answers but also creates opportunities: every new piece of the puzzle in dogs teaches us something about mastocytosis in humans, and vice versa.